US6750329B1
(en)
*
|
1989-05-05 |
2004-06-15 |
Research Development Foundation |
Antibody delivery system for biological response modifiers
|
US6710174B2
(en)
|
2001-09-13 |
2004-03-23 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of vascular endothelial growth factor receptor-1 expression
|
GB9506466D0
(en)
|
1994-08-26 |
1995-05-17 |
Prolifix Ltd |
Cell cycle regulated repressor and dna element
|
ATE198492T1
(de)
*
|
1994-08-26 |
2001-01-15 |
Aventis Pharma Gmbh |
Gentherapie von erkrankungen, die durch das immunsystem bedingt sind, mit hilfe eines zellspezifischen zellzyklusregulierten wirkstoffes
|
US7087582B1
(en)
|
1995-09-26 |
2006-08-08 |
Regents Of The University Of Michigan |
Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
|
GB9616685D0
(en)
*
|
1995-10-02 |
1996-09-25 |
Cancer Res Campaign Tech |
Antitumour vector constructs and methods
|
DE19605279A1
(de)
|
1996-02-13 |
1997-08-14 |
Hoechst Ag |
Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
|
AUPN816196A0
(en)
*
|
1996-02-19 |
1996-03-14 |
Forbio Research Pty Ltd |
Regulation of eukaryotic gene expression
|
DE19617851A1
(de)
*
|
1996-05-03 |
1997-11-13 |
Hoechst Ag |
Nukleinsäurekonstrukte mit Genen kodierend für Transportsignale
|
DE19639103A1
(de)
|
1996-09-24 |
1998-03-26 |
Hoechst Ag |
Nukleinsäurekonstrukte mit Hybridpromotoren für gentherapeutische Maßnahmen
|
DE19651443A1
(de)
|
1996-12-11 |
1998-06-18 |
Hoechst Ag |
Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
|
DE19701141C1
(de)
*
|
1997-01-16 |
1998-04-09 |
Hoechst Ag |
Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
|
DE19704301C1
(de)
*
|
1997-02-06 |
1998-03-26 |
Hoechst Ag |
Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie
|
US6294170B1
(en)
|
1997-08-08 |
2001-09-25 |
Amgen Inc. |
Composition and method for treating inflammatory diseases
|
EP0860445A1
(en)
*
|
1997-02-18 |
1998-08-26 |
Hoechst Aktiengesellschaft |
New nucleotide sequences for the cell cycle regulated expression of structural genes
|
US7112338B2
(en)
*
|
1997-03-12 |
2006-09-26 |
The Regents Of The University Of California |
Cationic liposome delivery of taxanes to angiogenic blood vessels
|
US5837283A
(en)
|
1997-03-12 |
1998-11-17 |
The Regents Of The University Of California |
Cationic lipid compositions targeting angiogenic endothelial cells
|
DE19710643A1
(de)
*
|
1997-03-14 |
1998-09-17 |
Hoechst Ag |
Der Promotor des cdc25B Genes und seine Verwendung in der Gentherapie
|
US6696423B1
(en)
|
1997-08-29 |
2004-02-24 |
Biogen, Inc. |
Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
|
GB9724829D0
(en)
*
|
1997-11-21 |
1998-01-21 |
Muller Rolf |
Transcription factor
|
DE19751587A1
(de)
|
1997-11-21 |
1999-07-29 |
Hoechst Marion Roussel De Gmbh |
Onkogen- oder virusgesteuerte Expressionssysteme
|
DE19756975A1
(de)
|
1997-12-20 |
1999-06-24 |
Hoechst Marion Roussel De Gmbh |
Bindungspartner für Inhibitoren von cyclinabhängigen Kinasen und ihre Verwendung zur Suche nach Inhibitoren, zur Diagnose oder zur Therapie einer Erkrankung
|
CZ121599A3
(cs)
|
1998-04-09 |
1999-10-13 |
Aventis Pharma Deutschland Gmbh |
Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
|
CA2325597C
(en)
*
|
1998-04-17 |
2010-09-21 |
Rigel Pharmaceuticals, Inc. |
Multiparameter facs assays to detect alterations in cellular parameters and to screen small molecule libraries
|
DE19831420A1
(de)
*
|
1998-07-14 |
2000-01-20 |
Hoechst Marion Roussel De Gmbh |
Expressionssysteme enthaltend chimäre Promotoren mit Bindungsstellen für rekombinante Transkriptionsfaktoren
|
WO2000006759A2
(en)
*
|
1998-07-27 |
2000-02-10 |
Valentis, Inc. |
Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same
|
WO2000015649A1
(en)
*
|
1998-09-11 |
2000-03-23 |
Thomas Jefferson University |
METHODS OF INHIBITING SMOOTH MUSCLE CELL PROLIFERATION AND PREVENTING RESTENOSIS WITH A VECTOR EXPRESSING RB2/p130
|
US6649158B1
(en)
*
|
1998-10-15 |
2003-11-18 |
Canji, Inc. |
Methods and compositions to induce antitumor response
|
US6867203B2
(en)
|
1998-12-29 |
2005-03-15 |
Abbott Laboratories |
Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
|
US6903077B1
(en)
|
1999-01-04 |
2005-06-07 |
University Of Vermont And State Agricultural College |
Methods and products for delivering nucleic acids
|
US6780986B1
(en)
|
1999-01-04 |
2004-08-24 |
University Of Vermont And State Agricultural College |
RIP60 nucleic acid and polypeptide sequences and uses therefor
|
DE19900743A1
(de)
|
1999-01-12 |
2000-07-13 |
Aventis Pharma Gmbh |
Neue komplexbildende Proteine
|
US6222096B1
(en)
*
|
1999-03-01 |
2001-04-24 |
Stine Biotechnology |
Promoter and construct for plant transformation
|
WO2000054839A2
(en)
*
|
1999-03-15 |
2000-09-21 |
Introgen Therapeutics, Inc. |
Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
|
DE60036929T2
(de)
*
|
1999-03-23 |
2008-08-07 |
Takara Bio Inc., Otsu |
Gentherapeutika
|
EP1754488A1
(en)
|
1999-05-24 |
2007-02-21 |
Introgen Therapeutics, Inc. |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
CA2376379C
(en)
*
|
1999-06-08 |
2007-08-07 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
JP4848113B2
(ja)
*
|
1999-09-09 |
2011-12-28 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
血管新生血管に対するタキサンの陽イオン性リポソーム送達
|
EP1225922A4
(en)
*
|
1999-11-03 |
2005-07-20 |
Medigene Oncology Gmbh |
EXPRESSION OF SELECTIVE TOXIN IN ENGINEERING ENDOTHELIAL CELLS
|
WO2001049868A1
(en)
*
|
1999-12-31 |
2001-07-12 |
Korea Research Institute Of Bioscience And Biotechnology |
Cancer cell-specific gene expression system
|
US7361643B2
(en)
|
2000-02-09 |
2008-04-22 |
University Of Puerto Rico |
Methods for inhibiting angiogenesis
|
ES2292587T3
(es)
*
|
2000-04-22 |
2008-03-16 |
Pharmedartis Gmbh |
Agentes apoptoticos.
|
US10293056B1
(en)
|
2000-05-24 |
2019-05-21 |
Board Of Regents, The University Of Texas System |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
DE60138465D1
(de)
|
2000-07-12 |
2009-06-04 |
Agensys Inc |
Neues tumor antigen das für diagnose und therapie von blasen-, eierstock-, lungen- und nierenkrebs verwendet werden kann
|
KR100488341B1
(ko)
*
|
2000-07-31 |
2005-05-11 |
주식회사 삼양제넥스 |
피972 유전자를 포함하는 유전자 전달체, 피972 유전자를 세포내에서 생산할 수 있는 아데노바이러스
|
US8071740B2
(en)
*
|
2000-11-17 |
2011-12-06 |
Vascular Biogenics Ltd. |
Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
|
US20070286845A1
(en)
*
|
2000-11-17 |
2007-12-13 |
Vascular Biogenics Ltd. |
Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
|
AU2003222427B8
(en)
|
2000-11-17 |
2010-04-29 |
Vascular Biogenics Ltd. |
Promoters exhibiting endothelial cell specificity and methods of using same
|
US20100282634A1
(en)
*
|
2000-11-17 |
2010-11-11 |
Dror Harats |
Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
|
US8039261B2
(en)
*
|
2000-11-17 |
2011-10-18 |
Vascular Biogenics Ltd. |
Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
|
US6838452B2
(en)
|
2000-11-24 |
2005-01-04 |
Vascular Biogenics Ltd. |
Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
|
CN1183250C
(zh)
*
|
2000-12-01 |
2005-01-05 |
卫健生物科技有限公司 |
高效表达肿瘤血管生成抑制因子的肿瘤细胞内特异性增殖的病毒及其构建方法
|
AU2002220257A1
(en)
*
|
2000-12-07 |
2002-06-18 |
Board Of Regents, The University Of Texas System |
Methods of treatment involving human mda-7
|
ZA200305980B
(en)
|
2001-02-12 |
2007-01-31 |
Res Dev Foundation |
Modified proteins, designer toxins, and methods of making thereof
|
DE60231263D1
(de)
*
|
2001-03-12 |
2009-04-02 |
Inst Of Gene And Brain Science |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) als Heilmittel für Nervenschäden
|
US20030003074A1
(en)
*
|
2001-06-14 |
2003-01-02 |
Macromed, Inc. |
Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
|
US20060159657A1
(en)
*
|
2001-06-14 |
2006-07-20 |
Macromed, Incorporated |
Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
|
US7101977B2
(en)
*
|
2001-07-17 |
2006-09-05 |
Research Development Foundation |
Therapeutic agents comprising pro-apoptotic proteins
|
DE60233744D1
(de)
|
2001-09-20 |
2009-10-29 |
Univ Texas |
Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper-komplexe mit elisa-tests
|
US6734017B2
(en)
|
2001-09-28 |
2004-05-11 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of vascular endothelial growth factor receptor-2 expression
|
EP2277887A3
(en)
*
|
2001-10-19 |
2011-02-16 |
Vascular Biogenics Ltd. |
Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
|
AU2002360610A1
(en)
*
|
2001-12-12 |
2003-07-09 |
Children's Hospital Of Orange County |
A novel regulatory element within the il-ialpha promoter and uses thereof
|
CA2477780A1
(en)
*
|
2002-03-05 |
2003-09-18 |
Board Of Regents, The University Of Texas System |
Methods of enhancing immune induction involving mda-7
|
US20040121955A1
(en)
*
|
2002-04-01 |
2004-06-24 |
Mulligan-Kehoe Mary Jo |
Methods for modulating angiogenesis
|
WO2003105761A2
(en)
*
|
2002-06-12 |
2003-12-24 |
Research Development Foundation |
Immunotoxin as a therapeutic agent and uses thereof
|
EP2269618A1
(en)
*
|
2002-08-12 |
2011-01-05 |
Jennerex Biotherapeutics ULC |
An oncolytic vaccinia virus for use in combination with a chemotherapy for treating cancer.
|
WO2004016744A2
(en)
*
|
2002-08-19 |
2004-02-26 |
Yun Yen |
Treatment of liver deseases
|
EP1549614A4
(en)
*
|
2002-10-03 |
2008-04-16 |
Targegen Inc |
VASCULATORY AGENTS AND METHODS FOR THEIR APPLICATION
|
US20050282814A1
(en)
*
|
2002-10-03 |
2005-12-22 |
Targegen, Inc. |
Vasculostatic agents and methods of use thereof
|
WO2004078124A2
(en)
*
|
2003-03-03 |
2004-09-16 |
Board Of Regents, The University Of Texas System |
Methods and compositions involving mda-7
|
AU2004285468B2
(en)
|
2003-10-22 |
2011-02-24 |
Fred Hutchinson Cancer Research Center |
Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
|
WO2005082396A2
(en)
*
|
2003-12-01 |
2005-09-09 |
Introgen Therapeutics, Inc. |
Use of mda-7 to inhibit infection by pathogenic organisms
|
US20070281041A1
(en)
*
|
2004-03-02 |
2007-12-06 |
Introgen Therapeutics, Inc. |
Compositions and Methods Involving MDA-7 for the Treatment of Cancer
|
WO2005085455A1
(en)
*
|
2004-03-09 |
2005-09-15 |
Kam Man Hui |
Compositions and methods for treating disease
|
KR20070011458A
(ko)
*
|
2004-04-08 |
2007-01-24 |
탈자진 인코포레이티드 |
키나제의 벤조트리아진 억제제
|
EP2290074B1
(en)
|
2004-05-28 |
2014-12-17 |
Asuragen, Inc. |
Methods and compositions involving microRNA
|
WO2006024034A1
(en)
|
2004-08-25 |
2006-03-02 |
Targegen, Inc. |
Heterocyclic compounds and methods of use
|
US20070066551A1
(en)
|
2004-09-07 |
2007-03-22 |
Keefe Anthony D |
Aptamer medicinal chemistry
|
CA2579374A1
(en)
|
2004-09-07 |
2006-03-30 |
Archemix Corp. |
Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
|
US7566701B2
(en)
*
|
2004-09-07 |
2009-07-28 |
Archemix Corp. |
Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
|
EP2287303B1
(en)
|
2004-11-12 |
2014-07-02 |
Asuragen, Inc. |
Methods and compositions involving miRNA and miRNA inhibitor molecules
|
JP2008531481A
(ja)
*
|
2005-02-08 |
2008-08-14 |
ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム |
癌の治療のための、mda−7を含む組成物および方法
|
US8822535B2
(en)
|
2005-04-20 |
2014-09-02 |
Fred Hutchinson Cancer Research Center |
Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
|
US8668905B2
(en)
*
|
2005-05-12 |
2014-03-11 |
University Of South Florida |
P53 vaccines for the treatment of cancers
|
CA2611720A1
(en)
*
|
2005-06-08 |
2006-12-14 |
Targegen, Inc. |
Methods and compositions for the treatment of ocular disorders
|
KR20090004839A
(ko)
*
|
2005-09-07 |
2009-01-12 |
제네렉스, 인코포레이티드 |
Gm-csf를 발현하는 폭스바이러스를 사용한 전이성및/또는 전신 파종성 암의 전신 치료법
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
EP1951684B1
(en)
|
2005-11-01 |
2016-07-13 |
TargeGen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
US8133900B2
(en)
*
|
2005-11-01 |
2012-03-13 |
Targegen, Inc. |
Use of bi-aryl meta-pyrimidine inhibitors of kinases
|
US8604042B2
(en)
*
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
CA2566267A1
(en)
*
|
2005-12-09 |
2007-06-09 |
University Health Network |
Thymidylate kinase mutants and uses thereof
|
US20090068158A1
(en)
*
|
2005-12-09 |
2009-03-12 |
Medin Jeffrey A |
Thymidylate kinase mutants and uses thereof
|
WO2007092944A2
(en)
*
|
2006-02-08 |
2007-08-16 |
Introgen Therapeutics, Inc. |
Compositions and methods involving gene therapy and proteasome modulation
|
WO2007098607A1
(en)
|
2006-03-03 |
2007-09-07 |
Amorfix Life Sciences Ltd. |
Methods and compositions to treat and detect misfolded-sod1 mediated diseases
|
WO2007127366A2
(en)
*
|
2006-04-25 |
2007-11-08 |
Targegen, Inc. |
Kinase inhibitors and methods of use thereof
|
US8481023B2
(en)
|
2006-09-15 |
2013-07-09 |
Ottawa Hospital Research Institute |
Oncolytic rhabdovirus
|
CA2663962A1
(en)
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
|
US20080131878A1
(en)
*
|
2006-12-05 |
2008-06-05 |
Asuragen, Inc. |
Compositions and Methods for the Detection of Small RNA
|
WO2008073919A2
(en)
*
|
2006-12-08 |
2008-06-19 |
Asuragen, Inc. |
Mir-20 regulated genes and pathways as targets for therapeutic intervention
|
KR20080084528A
(ko)
*
|
2007-03-15 |
2008-09-19 |
제네렉스 바이오테라퓨틱스 인크. |
종양살상형 백시니아 바이러스 암 치료
|
CA2584494A1
(en)
*
|
2007-03-27 |
2008-09-27 |
Jeffrey A. Medin |
Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
|
AR060702A1
(es)
|
2007-04-27 |
2008-07-10 |
Fundacion Inst Leloir |
Promotor inducible por especies reactivas del oxigeno y vector que lo comprende
|
EP2150618B1
(en)
|
2007-05-04 |
2017-10-11 |
University Health Network |
Il-12 immunotherapy for cancer
|
US20090203766A1
(en)
*
|
2007-06-01 |
2009-08-13 |
Archemix Corp. |
vWF aptamer formulations and methods for use
|
EP2198050A1
(en)
|
2007-09-14 |
2010-06-23 |
Asuragen, INC. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
US8071562B2
(en)
|
2007-12-01 |
2011-12-06 |
Mirna Therapeutics, Inc. |
MiR-124 regulated genes and pathways as targets for therapeutic intervention
|
WO2009114942A1
(en)
|
2008-03-20 |
2009-09-24 |
University Health Network |
Thymidylate kinase fusions and uses thereof
|
US8258111B2
(en)
|
2008-05-08 |
2012-09-04 |
The Johns Hopkins University |
Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
|
EP2391748A4
(en)
*
|
2009-01-28 |
2012-08-01 |
Antigen Express Inc |
LI-KEY HYBRID PEPTIDES MODULATING IMMUNE RESPONSE TO FLU
|
US20110045080A1
(en)
*
|
2009-03-24 |
2011-02-24 |
William Marsh Rice University |
Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
|
DK2477499T3
(en)
|
2009-09-14 |
2018-06-06 |
Sillajen Biotherapeutics Inc |
COMBINATION CANCER THERAPY WITH ONCOLYTIC VACCINIA VIRUS
|
AU2010329551B2
(en)
|
2009-12-10 |
2016-02-11 |
Turnstone Limited Partnership |
Oncolytic rhabdovirus
|
JP5875990B2
(ja)
|
2010-02-04 |
2016-03-02 |
イーメーズ インコーポレイテッド |
メチオニンγリアーゼ酵素を含む作製された酵素およびその薬理学的調製物
|
WO2011107100A1
(en)
|
2010-03-03 |
2011-09-09 |
Aarhus Universitet |
Methods and compositions for regulation of herv4
|
EP2605798A1
(en)
|
2010-07-12 |
2013-06-26 |
Universidad Autònoma de Barcelona |
Gene therapy composition for use in diabetes treatment
|
CA2816957A1
(en)
|
2010-11-07 |
2012-05-10 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
JP6121910B2
(ja)
|
2011-01-04 |
2017-04-26 |
シラジェン バイオセラピューティクス インコーポレイテッド |
腫瘍溶解性ワクシニアウイルスの投与による腫瘍抗原に対する抗体の生成および腫瘍特異的補体依存性細胞傷害の生成
|
CN103476931A
(zh)
|
2011-02-03 |
2013-12-25 |
米尔纳医疗股份有限公司 |
Mir-34的合成模拟物
|
JP2014506789A
(ja)
|
2011-02-03 |
2014-03-20 |
マーナ セラピューティクス インコーポレイテッド |
miR−124の合成模倣体
|
EP2718427B1
(en)
|
2011-06-08 |
2017-01-11 |
Children's Hospital of Eastern Ontario Research Institute Inc. |
Compositions for glioblastoma treatment
|
HUE039009T2
(hu)
|
2011-08-05 |
2018-12-28 |
Res Found Dev |
Javított eljárások és készítmények Olfml3-mediált angiogenesis modulálására
|
US9644241B2
(en)
|
2011-09-13 |
2017-05-09 |
Interpace Diagnostics, Llc |
Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
|
KR101421534B1
(ko)
|
2012-05-04 |
2014-07-24 |
전북대학교산학협력단 |
항균 활성 및 항암 활성이 강화된 리소좀의 제조방법
|
WO2013188873A1
(en)
|
2012-06-15 |
2013-12-19 |
Gencia Corporation |
Compositions and methods for enhancing immune responses
|
UA114108C2
(uk)
|
2012-07-10 |
2017-04-25 |
Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем |
Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
|
EP2692868A1
(en)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
|
US9803014B2
(en)
|
2012-10-24 |
2017-10-31 |
Research Development Foundation |
JAM-C antibodies and methods for treatment of cancer
|
WO2014078819A2
(en)
|
2012-11-16 |
2014-05-22 |
Transposagen Biopharmaceuticals, Inc. |
Site-specific enzymes and methods of use
|
ES2741147T3
(es)
|
2013-02-21 |
2020-02-10 |
Turnstone Lp |
Composición de vacuna
|
CA2921401A1
(en)
|
2013-08-14 |
2015-02-19 |
William Marsh Rice University |
Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
|
CN106659909B
(zh)
|
2013-08-21 |
2022-01-11 |
德克萨斯州大学系统董事会 |
用于靶向连接蛋白半通道的组合物和方法
|
CN105531371B
(zh)
|
2013-08-29 |
2021-04-09 |
得克萨斯大学体系董事会 |
用于治疗目的的工程改造的灵长类动物l-甲硫氨酸酶
|
AU2014312168B2
(en)
|
2013-08-29 |
2020-08-06 |
Board Of Regents, The University Of Texas System |
Engineered primate cystine/cysteine degrading enzymes as antineogenic agents
|
EP3492094A1
(en)
|
2013-08-30 |
2019-06-05 |
Board of Regents, The University of Texas System |
Administration of kynurenine depleting enzymes for tumor therapy
|
DK3076949T3
(da)
|
2013-12-04 |
2019-11-25 |
Univ Texas |
Fremgangsmåde til isolering af kræftcelle-afledte eksosomer
|
KR102356318B1
(ko)
|
2013-12-23 |
2022-01-26 |
아란세오 싱가포르 프라이빗 리미티드 |
엘라스토머 에틸렌/α-올레핀 공중합체를 위한 신규한 응결방지제
|
CA2934725C
(en)
|
2013-12-23 |
2023-07-25 |
Arlanxeo Singapore Pte. Ltd. |
Highly pure halogenated rubbers
|
KR102356319B1
(ko)
*
|
2013-12-23 |
2022-01-26 |
아란세오 싱가포르 프라이빗 리미티드 |
고무 산업을 위한 신규한 응결방지제
|
IL250833B
(en)
|
2014-08-29 |
2022-09-01 |
Univ Texas |
Administering enzymes to reduce the level of kynurenine in the treatment of tumors
|
WO2016033105A1
(en)
|
2014-08-29 |
2016-03-03 |
The Board Of Regents Of The University Of Texas System |
Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
|
WO2016110518A1
(en)
|
2015-01-07 |
2016-07-14 |
Universitat Autònoma De Barcelona |
Single-vector gene construct comprising insulin and glucokinase genes
|
US10457737B2
(en)
|
2015-02-09 |
2019-10-29 |
Research Development Foundation |
Engineered immunoglobulin Fc polypeptides displaying improved complement activation
|
EP3265565B1
(en)
|
2015-03-04 |
2020-08-12 |
Board of Regents, The University of Texas System |
Methods of treating cancer harboring hemizygous loss of tp53
|
EP3307890A1
(en)
|
2015-06-10 |
2018-04-18 |
Board of Regents, The University of Texas System |
Use of exosomes for the treatment of disease
|
ES2886599T3
(es)
|
2015-06-17 |
2021-12-20 |
Poseida Therapeutics Inc |
Composiciones y métodos para dirigir proteínas a loci específicos en el genoma
|
AU2016298210B2
(en)
|
2015-07-28 |
2021-12-09 |
Board Of Regents, The University Of Texas System |
Implant compositions for the unidirectional delivery of therapeutic compounds to the brain
|
WO2017040380A2
(en)
|
2015-08-28 |
2017-03-09 |
Research Development Foundation |
Engineered antibody fc variants
|
SG10202104058XA
(en)
|
2015-10-14 |
2021-05-28 |
Bio Path Holdings Inc |
P-ethoxy nucleic acids for liposomal formulation
|
EP3371221A2
(en)
|
2015-11-07 |
2018-09-12 |
MultiVir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
JP6987068B2
(ja)
|
2015-11-09 |
2021-12-22 |
ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia |
癌マーカーおよび治療標的としてのグリピカン2
|
KR20180100122A
(ko)
|
2015-12-02 |
2018-09-07 |
주식회사 에스티사이언스 |
당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
|
ES2861449T3
(es)
|
2015-12-02 |
2021-10-06 |
Stcube & Co Inc |
Anticuerpos y moléculas que se unen inmunoespecíficamente a BTN1A1 y los usos terapéuticos de los mismos
|
JP7098527B2
(ja)
|
2016-02-26 |
2022-07-11 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
コネキシン(Cx)43ヘミチャネル結合抗体及びその使用
|
KR20180114946A
(ko)
|
2016-03-02 |
2018-10-19 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
면역요법을 위한 sting 활성화 나노백신
|
KR102367074B1
(ko)
|
2016-03-29 |
2022-02-25 |
주식회사 에스티큐브 |
글리코실화된 pd-l1에 특이적인 이중 기능 항체 및 이의 사용 방법
|
KR20230031373A
(ko)
|
2016-03-29 |
2023-03-07 |
주식회사 에스티큐브앤컴퍼니 |
글리코실화된 면역체크포인트 단백질에 특이적으로 결합하는 항체를 선택하는 방법
|
EP4029950A1
(en)
|
2016-04-29 |
2022-07-20 |
Board of Regents, The University of Texas System |
Targeted measure of transcriptional activity related to hormone receptors
|
WO2018009663A1
(en)
|
2016-07-06 |
2018-01-11 |
Board Of Regents, The University Of Texas System |
Human-enzyme mediated depletion of cystine for treating patients with cystinuria
|
KR20190031299A
(ko)
|
2016-07-20 |
2019-03-25 |
주식회사 에스티큐브 |
글리코실화된 pd-l1에 결합하는 항체의 조합을 사용하는 암 치료 방법
|
US9963498B2
(en)
|
2016-08-18 |
2018-05-08 |
Wisconsin Alumni Research Foundation |
Peptides that inhibit syndecan-1 activation of VLA-4 and IGF-1R
|
KR20190053905A
(ko)
|
2016-09-16 |
2019-05-20 |
바이오-패쓰 홀딩스 인크. |
리포솜 안티센스 올리고뉴클레오타이드와의 병용 요법
|
US10316037B1
(en)
|
2016-11-04 |
2019-06-11 |
Yale University |
Compounds and methods for treating cancer
|
CA3043356A1
(en)
|
2016-11-09 |
2018-05-17 |
Musc Foundation For Research Development |
Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
|
JP2020510624A
(ja)
|
2016-12-12 |
2020-04-09 |
マルチビア インコーポレイテッド |
がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物
|
WO2018156973A1
(en)
|
2017-02-24 |
2018-08-30 |
Board Of Regents, The University Of Texas System |
Assay for detection of early stage pancreatic cancer
|
CN107034215B
(zh)
*
|
2017-03-29 |
2019-12-13 |
华中科技大学同济医学院附属协和医院 |
一种cux1蛋白可结合dna片段及在cux1活性检测中的应用
|
US10865403B2
(en)
|
2017-05-12 |
2020-12-15 |
Board Of Regents, The University Of Texas System |
Engineered primate cystine/cysteine degrading enzymes for therapeutic uses
|
MX2019013458A
(es)
|
2017-05-12 |
2020-01-15 |
Univ Texas |
Disminucion de homocisteina mediada por enzimas humanas para el tratamiento de pacientes con hiperhomocisteinemia y homocistinuria.
|
AU2018277838A1
(en)
|
2017-05-31 |
2019-12-19 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
|
KR20200024158A
(ko)
|
2017-05-31 |
2020-03-06 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
|
JP2020522562A
(ja)
|
2017-06-06 |
2020-07-30 |
ストキューブ アンド シーオー., インコーポレイテッド |
Btn1a1又はbtn1a1リガンドに結合する抗体及び分子を用いて癌を治療する方法
|
EP3694545A4
(en)
|
2017-10-11 |
2021-12-01 |
Board Of Regents, The University Of Texas System |
HUMAN PD-L1 ANTIBODIES AND METHOD OF USING THEM
|
WO2019126578A1
(en)
|
2017-12-20 |
2019-06-27 |
Poseida Therapeutics, Inc. |
Compositions and methods for directing proteins to specific loci in the genome
|
WO2020036635A2
(en)
|
2018-03-19 |
2020-02-20 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
|
US20210214445A1
(en)
|
2018-03-23 |
2021-07-15 |
Board Of Regents, The University Of Texas System |
Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
|
WO2019191279A2
(en)
|
2018-03-27 |
2019-10-03 |
Board Of Regents, The University Of Texas System |
Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
|
EP3883955A1
(en)
|
2018-11-19 |
2021-09-29 |
Board of Regents, The University of Texas System |
A modular, polycistronic vector for car and tcr transduction
|
SG11202105609RA
(en)
|
2018-11-28 |
2021-06-29 |
Univ Texas |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
EP3886874A1
(en)
|
2018-11-29 |
2021-10-06 |
Board of Regents, The University of Texas System |
Methods for ex vivo expansion of natural killer cells and use thereof
|
US20220136011A1
(en)
|
2019-02-08 |
2022-05-05 |
Board Of Regents, The University Of Texas System |
Telomerase-containing exosomes for treatment of diseases associated with aging and age-related organ dysfunction
|
WO2020227711A1
(en)
|
2019-05-09 |
2020-11-12 |
FUJIFILM Cellular Dynamics, Inc. |
Methods for the production of hepatocytes
|
US10945981B2
(en)
|
2019-05-17 |
2021-03-16 |
Cancer Prevention Pharmaceuticals, Inc. |
Methods for treating familial adenomatous polyposis
|
WO2021016062A1
(en)
|
2019-07-19 |
2021-01-28 |
The Children's Hospital Of Philadelphia |
Chimeric antigen receptors containing glypican 2 binding domains
|
AU2020344675A1
(en)
|
2019-09-13 |
2022-03-31 |
Elektrofi, Inc. |
Compositions and methods for the delivery of therapeutic biologics for treatment of disease
|
EP4041767A1
(en)
|
2019-09-26 |
2022-08-17 |
StCube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
KR20220088438A
(ko)
|
2019-10-09 |
2022-06-27 |
주식회사 에스티큐브앤컴퍼니 |
글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법
|
US20220380765A1
(en)
|
2019-11-02 |
2022-12-01 |
Board Of Regents, The University Of Texas System |
Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
CA3161733A1
(en)
|
2020-01-07 |
2021-05-15 |
Everett Stone |
Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
|
US20230106973A1
(en)
|
2020-02-17 |
2023-04-06 |
Board Of Regents, The University Of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
CA3178726A1
(en)
|
2020-05-21 |
2021-11-25 |
Gregory LIZEE |
T cell receptors with vgll1 specificity and uses thereof
|
WO2021247836A1
(en)
|
2020-06-03 |
2021-12-09 |
Board Of Regents, The University Of Texas System |
Methods for targeting shp-2 to overcome resistance
|
US20230266325A1
(en)
|
2020-06-30 |
2023-08-24 |
Lunglife Ai, Inc. |
Methods for detecting lung cancer
|
AU2021377699A1
(en)
|
2020-11-13 |
2023-06-15 |
Catamaran Bio, Inc. |
Genetically modified natural killer cells and methods of use thereof
|
WO2022115611A1
(en)
|
2020-11-25 |
2022-06-02 |
Catamaran Bio, Inc. |
Cellular therapeutics engineered with signal modulators and methods of use thereof
|
EP4281116A1
(en)
|
2021-01-19 |
2023-11-29 |
William Marsh Rice University |
Bone-specific delivery of polypeptides
|
GB2603166A
(en)
|
2021-01-29 |
2022-08-03 |
Thelper As |
Therapeutic and Diagnostic Agents and Uses Thereof
|
CA3228262A1
(en)
|
2021-08-04 |
2023-02-09 |
The Regents Of The University Of Colorado, A Body Corporate |
Lat activating chimeric antigen receptor t cells and methods of use thereof
|
IL311790A
(en)
|
2021-10-05 |
2024-05-01 |
Chang Hao Ming |
Natural killer cells and methods of their use
|
CA3236038A1
(en)
|
2021-10-20 |
2023-04-27 |
Takeda Pharmaceutical Company Limited |
Compositions targeting bcma and methods of use thereof
|
WO2023076880A1
(en)
|
2021-10-25 |
2023-05-04 |
Board Of Regents, The University Of Texas System |
Foxo1-targeted therapy for the treatment of cancer
|
GB202201137D0
(en)
|
2022-01-28 |
2022-03-16 |
Thelper As |
Therapeutic and diagnostic agents and uses thereof
|
WO2023172514A1
(en)
|
2022-03-07 |
2023-09-14 |
Catamaran Bio, Inc. |
Engineered immune cell therapeutics targeted to her2 and methods of use thereof
|
US20230365708A1
(en)
|
2022-04-01 |
2023-11-16 |
Board Of Regents, The University Of Texas System |
Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
|
WO2023211972A1
(en)
|
2022-04-28 |
2023-11-02 |
Medical University Of South Carolina |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
WO2023220083A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
WO2023230531A1
(en)
|
2022-05-24 |
2023-11-30 |
Lunglife Ai, Inc. |
Methods for detecting circulating genetically abnormal cells
|
US20240010742A1
(en)
|
2022-06-10 |
2024-01-11 |
Research Development Foundation |
Engineered fcriib selective igg1 fc variants and uses thereof
|